Solexa, acquired by Illumina in January 2007, developed systems for the comprehensive and economical analysis of individual genomes. The ability to read individual genomes quickly and economically will be a fundamental tool in the development of the biological and medical sciences in the twenty-first century. Solexa’s goal was to reduce the cost of human resequencing to a few thousand dollars and achieve the so-called ‘$1,000 genome’ for use in a wide range of applications from basic research through clinical diagnostics.

Amadeus sold its final holdings in Illumina in July 2008.